Lumateperone
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the pyridopyrroloquinoxaline and butyrophenone families.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the pyridopyrroloquinoxaline and butyrophenone families. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate), and for major depressive disorder as an adjunctive therapy only (with an oral antidepressant).
It is developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb. Lumateperone was approved for medical use in the US in December 2019 with an initial indication for schizophrenia. It became available in February 2020.
It has also been identified as a potent vesicular monoamine transporter 2 (VMAT2) inhibitor ( = 62 nM).
Text derived from https://en.wikipedia.org/w/index.php?oldid=1378397665 under CC BY-SA 4.0; modifications have been made.